Development of resistance to zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy

AIDS

Volumn 10, Issue 6, 1996, Pages 625-633

  Nielsen, Claus ^a   Bruun, Louise ^a   Mathiesen, Lars R ^b   Pedersen, Court ^b,c   Gerstoft, Jan ^c  

^a STATENS SERUM INSTITUT   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

CD4+ lymphocytes; Didanosine; HIV; Macrophages; Non syncytium inducing; Resistance; Syncytium inducing; Zidovudine

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CODON; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE CULTURE; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS RESISTANCE;

EID: 0029984169     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199606000-00008     Document Type: Article

References (25)

1. Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 246:1155-1158.
2. Nielsen C, Gotzsche PC, Nielsen CM, Gerstoft J, Vestergaard BF: Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during zidovudine therapy. Antiviral Res 1991, 18:303-316.
3. Reichman RC, Tejani N, Lambert JL, et al.: Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI. Antiviral Res 1993, 20:267-277.
4. Kellam P, Boucher CA, Larder BA: Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992, 89:1934-1938.
5. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246:1155-1158.
6. St Clair MH, Martin JL, Tudor-Williams G, et al.: Resistance to ddI and sensitivity to AZT induced by mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
7. Boucher CAB, Tersmette M, Lange JMA, et al.: Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 1990, 336:585-590.
8. Larder BA, Kellam P, Kemp SD: Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 1993, 365:451-453.
9. Karlsson A, Parsmyr K, Aperia K, Sandström E, Fenyö EM, Albert J: MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance. J Infect Dis 1994, 169:1367-1375.
10. Boucher CAB, Lange JMA, Miedema FF, et al.: HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992, 6:1259-1264.
11. Gerstoft J, for the Nordic HIV therapy Group: Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection: the Alter Study. 5th European Conference on Clinical Aspects and Treatment of HIV Infection. Copenhagen, September 1995 [abstract 82].
12. Nielsen C, Nielsen CM, Pedersen JL, et al.: Isolation of HIV from cultures of purified CD4+ lymphocytes. J Virol Methods 1991, 35:15-25.
13. Nielsen CM, Bygbjerg IC, Vestergaard BF: Detection of HIV antigens in eluates from whole blood collected on filterpaper. Lancet 1987, 1:566-567.
14. Valentin A, Von Gegerfelt A, Matsuda S, Nilsson K, Åsjö B: In vitro maturation of mononuclear phagocytes and susceptibility to HIV-1 infection. J Acquir Immune Defic Syndr 1991, 4:751-759.
15. Larder BA, Kellam P, Kemp SD: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991, 5:137-144.
16. Shafer RW, Kozal MJ, Winters MA, et al.: Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J infect Dis 1994, 169:722-729.
17. Koot M, Vos AHV, Keet RPM, et al.: HIV-1 biological phenotype in long-term infected individuals evaluates with an MT-2 cocultivation assay. AIDS 1992, 6:49-54
18. Kellam P, Boucher CAB, Jolanda MGH, et al.: Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994, 75:341-351.
19. Masquelier B, Pellegrin I, Ruffault A, et al.: Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:330-334.
20. McLeod GX, McGrath JM, Ladd EA, Hammer SM: Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay. Antimicrob Agents Chemother 1992, 36:920-925.
21. Gao WY, Shirasaka T, Johns DG, et al.: Differential phosphorylation of azidothymidine, dideoxycylidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993, 91:2326-2333.
22. Eron JJ, Chow YK, Vidler J, et al.: Decreased didanosine (ddI) susceptibility of HIV-1 clinical isolates and molecular clones assayed on peripheral blood mononuclear cells. J Cell Biochem 1992, 16:80-85.
23. Perno CF, Yarchoan R, Cooney DA, et al.: Replication of human immunodeficiency virus in monocytes. J Exp Med 1989, 169:933-951.
24. Kojima E, Shirasaka T, Anderson, et al.: Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J Infect Dis 1995, 171:1152-1158.
25. Delforge M-L, Liesnard C, Debaisieux L, et al.: In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine. [letter] AIDS 1995, 9:89-90.